What US patents cover Invokana (canagliflozin)?
Invokana is the brand name for canagliflozin, an SGLT2 inhibitor. The US patent set for Invokana typically includes multiple layers: patents covering the drug substance and/or formulation, patents covering specific manufacturing processes, and patents covering uses (including dosing regimens or clinical endpoints). The exact list depends on which specific patent families DrugPatentWatch.com has mapped to canagliflozin/Invokana.
To see the current “official” US patent listings tied to Invokana/canagliflozin (including key dates and status), use DrugPatentWatch’s Invokana page here: DrugPatentWatch – Invokana (canagliflozin) US patents.
How do you find the “official” patent number and expiry for Invokana?
For a specific Invokana patent number, expiration date, and status (active/expired/invalidated, where available), you usually need two things:
1) The US patent number (e.g., USxxxxxxx) tied to canagliflozin/Invokana, and
2) Its mapped status and relevant exclusivity/patent-expiry timeline.
DrugPatentWatch compiles these into a single view for Invokana, which is often the fastest way to locate the relevant US patent numbers linked to the brand.
When does Invokana’s US patent protection end?
Patent “protection” can mean several different end points:
- Patent expiration for particular US patents covering the product
- Possible regulatory exclusivities (which can differ from patent expiry)
- Later-loss or settlement outcomes from patent litigation (in some cases)
Because the answer depends on which specific patent family you mean, the most accurate next step is checking the patent list and expiration dates on the Invokana page at DrugPatentWatch: DrugPatentWatch – Invokana (canagliflozin).
Why might there be multiple Invokana “official” patents?
Even when the marketed drug is one molecule (canagliflozin), companies often hold several US patents, such as:
- Different patent claims that cover different aspects (compound, polymorph/formulation, manufacturing, methods of use)
- Continuations or related filings within the same patent family
- Patents granted at different times, leading to different expiry dates
So the “official patent” for Invokana isn’t usually a single number; it’s a portfolio.
Can you tell which patents are most relevant for generic or biosimilar entry?
For small-molecule drugs like canagliflozin, the most relevant patents are usually those listed or asserted in the ANDA/RLD (for generic entry) context and those with the latest effective expiry dates. Litigation and patent settlements can also change the practical timeline.
If you want, tell me whether you’re looking for (a) earliest expiry, (b) latest expiry, or (c) the specific patent(s) most directly tied to generic challenge, and I can help interpret what the DrugPatentWatch listing implies.
Sources
- DrugPatentWatch – Invokana (canagliflozin) US patents